Article Sidebar

Submitted
July 31, 2024
Published
August 20, 2024
Download
PDF
Statistic
Read Counter : 316 Download : 6

Main Article Content

Abstract

Drugs Related Problems (DRPs) are problems related to patient treatment that can affect the effectiveness and safety of therapy. Breast cancer patients who receive chemotherapy usually consists of a combination of several drugs. Administration of a combination of chemotherapy drugs can cause DRPs. This study aims to determine the actual and potential incidence of DRPs and their causes in breast cancer patients at the KRMT Wongsonegoro Regional General Hospital, Semarang in 2022. This research was conducted observationally with a cross-sectional research design and retrospective data collection by observing medical record data of breast cancer patients. There were 30 samples that met the inclusion and exclusion criteria. The classification of DRPs refers to the Regulation of the Minister of Health of the Republic of Indonesia Number 34 of 2021 concerning Standards of Pharmaceutical Services in Clinics. DRPs were analyzed using the National Guidelines for Medical Services for Breast Cancer Management in 2018. Analysis of potential drug interactions used medscape.com. Data analysis was carried out descriptively. The results showed that the most frequently used chemotherapy regimen was cyclophosphamide + doxorubicin + fluorouracil (76.67%). All patient samples experienced actual and potential DRPs with the cause being indication without medication (46.67%), medication without indication (0%), too high a dose (90%), too low a dose (100%), side effects undesired (100%), potential drug interactions (100%) and duration of treatment (53.2%). The prevalence of DRPs in our setting was high so that it could affect therapy outcomes of patient. Therefore, it is hoped that there will be an evaluation to reduce the prevalence of DRPs, by optimizing clinical pharmacy service practices such as reviewing prescriptions, monitoring effectiveness therapy and adverse drug reaction also conducting interprofessional collaboration.

Keywords

Drugs Related Problems (DRPs) Kanker Payudara Kemoterapi

Article Details

References

  1. Adiputra. I. M. S, Trisnadewi. N. W, Oktaviani. N. P. W, Munthe. S. A, Hulu. V. T, Budiastutik. I, Faridi. A, Ramdany. R, Fitriani. R. J, Tania. P.O.A, Rahmiati. B. F, Lusiana. S. A, Susilawaty. A, dan Suryana, 2021, Metodologi Penelitian Kesehatan (Watrianthos. Ronal dan J. Simarmata, Eds.), Yayasan Kita Menulis.
  2. Akram. M., Iqbal, M., Daniyal, M., dan Khan, A. U, 2017, Awareness and current knowledge of breast cancer, In Biological Research, Vol. 50, Issue 1, BioMed Central Ltd.
  3. Arisanti. J. P., Saptarina. N., dan Andarini. Y. D., 2020, Evaluasi Penggunaan Obat Kemoterapi Pada Penderita Kanker Payudara Di RSUP DR. Seoradji Tirtonegoro Periode 2018, Pharmashipa, 4(2), 1–8.
  4. Ashariati. A., 2019, Manajemen Kanker Payudara Komprehensif (Ashariati. A, Sedana. M. P, Bintoro. U. Y, Diansyah. M. N, Amrita. P. N. A, Savitri. M, Romadhon. P. Z, dan Permatasari. A, Eds.).
  5. Ayalew S. E., Engidawork. E., Yesuf. T. A., dan Ketema, E. B., 2015, Drug Related Problems in Chemotherapy of Cancer Patients, Journal of Cancer Science dan Therapy, 07(02).
  6. Azim Jr. H. A., Azambuja. E. de., Colozza. M., Bines. J., dan Piccart. M. J., 2011, Long-term Toxic Effect of Adjuvant Chemotherapy Breast Cancer, Annals of Oncology, 22(9), 1939-1947.
  7. Begg. E. J., dan Chin. Paul. K.L., 2012, A unified pharmacokinetic approach to individualized drug dosing, British Journal of Clinical Pharmacology, 73(3), 335–339.
  8. Cameron. D., 2009, Management of chemotherapy-associated febrile neutropenia, British Journal of Cancer, 101, S18–S22.
  9. Cardoso. F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., dan Senkus, E., 2019, Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 30(8), 1194–1220.
  10. Cecily. V. Breast Cancer., 2021, dalam Dipiro. J. T., Dipiro. C.V., Schwinghammer. T. L dan Wells. B. G., ed., Pharmacotherapy Handbook Eleventh Edition (Elevent Edition), hal. 687-698, Mc Graw Hill.
  11. Crozier. M., Tubman, J., Fifield, B. A., Ferraiuolo, R. M., Ritchie, J., Zuccato, K., Mailloux, E., Sinha, I., Hamm, C., dan Porter, L. A., 2022, Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells, Plos One, 17(9).
  12. Darmayanti. E. Y., Puspitasari, C. E., dan Hasina, R., 2021, Profil Drug Related Problems (DRPs) Penggunaan Antibiotik pada Pasien Anak dengan Diare Infeksi di RSUD Provinsi NTB Tahun 2018, Jurnal Sains Dan Kesehatan, 3(3), 500–504.
  13. Degu. A., dan Kebede, K., 2021, Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia: A hospital-based retrospective cross-sectional study, Journal of Oncology Pharmacy Practice, 27(1), 88–98.
  14. Desweni. E., Harahap. W. A., dan Afriwardi. A., 2021, Pemeriksaan Payudara Sendiri (SADARI) dengan Stadium Kanker Payudara, Journal of Telenursing (JOTING), 3(2), 629–635.
  15. Els. V., 2021, Artikel Tinjauan Pustaka Tinjauan Pustaka Keterkaitan Cara Kerja Kontrasepsi Hormonal Dengan Risiko Terjadinya Kanker Payudara, Essence of Scientific Medical Journal, 19(2), 25–31.
  16. Fauzi. D. A. S., Hajrah. H., dan Sastyarina. Y., 2021, Evaluasi Penggunaan Obat Antiemetik pada Penderita Kanker Payudara Pasca Kemoterapi, Proceeding of Mulawarman Pharmaceuticals Conferences, 14, 222–227.
  17. Fisusi. F. A., dan Akala. E. O., 2019, Drug Combinations in Breast Cancer Therapy, Pharmaceutical Nanotechnology, 7(1), 3–23.
  18. Globocan., 2020, The Global Cancer Observatory, International Agency for Research on Cancer.
  19. Hardjono. S. Obat Antihistamin., 2008, dalam Siswandono dan Soekardjo. B., ed., Kimia Medisinal Edisi 2, hal. 185-206, Airlangga University Press.
  20. Haryani. S., 2022, Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Payudara di RSUP Fatmawati Periode Februari 2021, Jurnal Farmasi Klinik-Base Practice, 1(1).
  21. Herawati. A., Rijal. S., St. A. A. F., Purnamasari. R., Abdi. D. A., dan Wahid. S., 2021, Karakteristik Kanker Payudara, Fakumi Medical Journal, 1(1), 44–53.
  22. Data Profil Rumah Sakit KRMT Wongsonegoro Semarang, Data Diperoleh Melalui Situs Internet: https://rsud.semarangkota.go.id. Diunduh pada tanggal 28 maret 2023.
  23. Data Farmakokinetik dan Farmakodinamik Obat Kemoterapi, Data Diperoleh Melalui Situs Internet: https://www.drugs.com. Diunduh pada tanggal 3 Agustus 2023.
  24. Irawati. I., dan Sardjan. M., 2022, Pola Peresepan Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang, Pharmademica: Jurnal Kefarmasian Dan Gizi, 1(2), 80–85.
  25. Juwita. D. A., Almahdy, dan Afdhila. R. 2018, Pengaruh Karakteristik Pasien Terhadap Kualitas Hidup Terkait Kesehatan Pada Pasien Kanker Payudara di RSUP Dr.M. Djamil Padang, Indonesia, Jurnal Sains Farmasi dan Klinis, 5(2), 126–133.
  26. Kalli. S., Semine. A., Cohen. S., Naber. S. P., Makim. S. S., dan Bahl. M., 2018, American Joint Committee On Cancer’s Staging System For Breast Cancer, Eighth Edition: What The Radiologist Needs To Know, Radiographics, 38(7), 1921–1933.
  27. Ketut. S., dan Kartika. S. L. M. K., 2022, Kanker Payudara: Diagnostik, Faktor Resiko, dan Stadium, Ganesha Medicana Journal, 2(1), 42–48.
  28. Listiana. S. A., Setiawan. D., dan Susanti., 2012, Identifikasi Permasalahan Dosis Dan Interaksi Obat Pada Paien Askes Dan Umum Penderita Epilepsi Di RSUD Prof. Dr. Mrgono Soekardjo Purwokerto, Pharmacy, 9(2), 58–73.
  29. Data Interaksi Obat, Data Diperoleh Melalui Situs Internet: https://reference.medscape.com/drug-interactionchecker. Diunduh pada tanggal 6 Juli 2023.
  30. Mirsyad. A., Azis. B. G., K., Karim. M., Purnamasari. R., Sulvita. K. N., dan Husni T. A., 2022, Hubungan Usia Pasien Dengan Tingkat Stadium Kanker Payudara Di RS Ibnu Sina Makassar 2018, Fakumi Medical Journal, 2(2), 109–115.
  31. NHS Breast Cancer, 2014, Chemotherapy Protocol Breast Cancer Cyclophosphamide-Doxorubicin, University Hospital Southamphon, hal. 1-6.
  32. NHS Breast Cancer, 2020, Chemotherapy Protocol Breast Cancer Cyclophosphamide-Epirubicin (60)-Fluorouracil, University Hospital Southamphon, hal. 1-6.
  33. Pandrangi. S. L., Chittineedi. P., Chikati. R., Mosquera. J. A. N., Llaguno. S. N. S., Mohiddin. G. J., Lanka. S., Chalumuri. S. S., dan Maddu. N., 2022, Role of Lipoproteins in the Pathophysiology of Breast Cancer, In Membranes, Vol. 12, Issue 5.
  34. Permenkes RI., 2016, Rencana Aksi Nasional Kesehatan Lanjut Usia, 1–96.
  35. Permenkes RI., 2018 Pedoman Nasional Pelayanan Kedokteran Kanker Payudara.
  36. Permenkes RI., 2021, Standar Pelayanan Kefarmasian di Klinik, 1–101.
  37. Rahmawati, A., dan Lasut, P., 2020, Kanker Payudara Pasca Kemoterapi dengan Neutropenia: Laporan Kasus, Medical Scope Journal, 2(1).
  38. Rotua. S. Y., Pratiwi. A., Darmirani. Y., 2021, Seminar Tentang Identifikasi DRPs Pada Pasien Geriatri Yang Menerima Resep Polifarmasi Pada Penyakit Stroke, Jurnal Pengabdian Kepada Masyarakat, 1(2), 2775–2437.
  39. Saputra. L. I., Frisitiohady. A., dan Hajrul M. M., 2022, Review: Patofisiologi, Epidemiologi, dan Lini Sel Kanker Payudara, Pharmauho: Jurnal Farmasi, 8(1).
  40. Schindler. E., Richling. I., dan Rose, O., 2021, Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation, International Journal of Clinical Pharmacy, 43, 726–730.
  41. Setiawan. M., Lestari. D. R., dan Rachmawati. K., 2018, Hubungan Lama Kemoterapi Dengan Konsep Diri Pasien Kanker Payudara Yang Menjalani Kemoterapi Di RSUD Ulin Banjarmasin, Dinamika Kesehatan, 9(2), 429–443.
  42. Shinta. N., dan Surarso. B., 2016, Terapi Mual Muntah Pasca Kemoterapi, Jurnal THT, 9(2), 74–83.
  43. Su. Y. J., Yan. Y. D., Wang. W. J., Xu. T., Gu. Z. C., Bai. Y. R., dan Lin. H. W., 2021, Drug-related problems among hospitalized cancer pain patients: An investigative single-arm intervention trial, Annals of Palliative Medicine, 10(2), 2008–2017.
  44. Sukandar. E. Y., Hartini, S., dan Rizkita, P., 2013, Evaluasi Reaksi Obat Merugikan pada Pasien Kemoterapi Kanker Payudara di Salah Satu Rumah Sakit di Bandung (Evaluation of Adverse Effects in Patient with Breast Cancer Chemotherapy at A Hospital in Bandung), Jurnal Ilmu Kefarmasian Indonesia, 12(9), 183–192.
  45. Sun. Y. S., Zhao. Z., Yang. Z. N., Xu. F., Lu. H. J., Zhu. Z. Y., Shi. W., Jiang. J., Yao. P. P., dan Zhu. H. P., 2017, Risk factors and preventions of breast cancer, In International Journal of Biological Sciences, Vol. 13, Issue 11, pp. 1387–1397, Ivyspring International Publisher.
  46. Thakur. P., Seam. R. K., Gupta. M. K., Gupta. M., Sharma. M., dan Fotedar. V., 2017, Breast cancer risk factor evaluation in a Western Himalayan state: A case-control study and comparison with the Western World, South Asian Journal of Cancer, 6(3), 106–109.
  47. Tuloli. T. S., Pakaya. M. S., dan Pratiwi. S. D., 2021, Identifikasi Drug Related Problems (DRPs) Pasien Hipertensi di RS Multazam Kota Gorontalo, Indonesian Journal of Pharmaceutical Education (e-Journal), 1(1), 2775–3670.
  48. Wangsa. I. G. M. S., Niryana. I. W., Adiputra. P. A. T., dan Dewi. N. P. A., 2018, Gambaran stadium dan jenis histopatologi kanker payudara di Subbagian Bedah Onkologi RSUP Sanglah Denpasar tahun 2015-2016, Intisari Sains Medis, 9(1), 80–84.
  49. Wulandari. Y., Kumala. S., Keban. S. A., dan Julian. E. D., 2020, The role of pharmacist in handling drug-related problems in breast cancer patients at Dr. Cipto Mangunkusumo Hospital, International Journal of Advances in Medicine, 7(3), 364.